Abstract
Provided herein are novel pyrrolidinyl derivatives as HCN2 modulators, pharmaceutical compositions, use of such compounds in treating central nervous system (CNS) and psychiatric disorders, namely, autism, mood disorders and schizophrenia, and processes for preparing such compounds.